WARNING: Market Shock Imminent

Join us on September 29 at 4 p.m. ET at the Market Shock 2022 event to find out what’s coming and how to profit.

Thu, September 29 at 4:00PM ET
 
 
 
 

ABBV Stock Slips as AbbVie Faces Opioid Lawsuits

  • AbbVie (ABBV) just released its Q2 financial results.
  • Furthermore, AbbVie has set aside more than $2 billion to settle lawsuits related to the company's past opioid sales.
  • ABBV stock headed lower today due to these news items.
ABBV stock - ABBV Stock Slips as AbbVie Faces Opioid Lawsuits

Source: Piotr Swat / Shutterstock.com

AbbVie (NYSE:ABBV) recently published the company’s second-quarter 2022 financial data. The results weren’t very different from what Wall Street’s analysts had expected. However, probably due to AbbVie setting aside billions of dollars to resolve lawsuits concerning the marketing of opioid products, ABBV stock hit the skids today.

AbbVie’s Q2 2022 results weren’t terrible. The company’s adjusted diluted earnings of $3.37 per share slightly beat the analyst consensus estimate of $3.32 per share. Moreover, AbbVie’s quarterly revenue of $14.6 billion, up 4.5% year-over-year (YOY), was almost in line with the forecast of $14.7 billion.

A particular highlight was AbbVie’s second-quarter 2022 net revenue from U.S. sales of immunology drug Humira. That figure totaled $4.66 billion, up 9.6% YOY.

In other words, AbbVie’s quarterly results wouldn’t typically cause ABBV stock to slide. However, there was another news item that seems to be impacting the stock’s price action today.

What’s Moving ABBV Stock?

Reportedly, AbbVie has set aside around $2 billion to resolve thousands of lawsuits against the company’s Allergan unit. These lawsuits pertain to Allergan’s alleged marketing of opioid products. Among these products is Allergan’s opioid-based painkiller, Kadian.

More than 3,000 of these lawsuits have been filed by U.S. state and local governments against AbbVie/Allergan. The company has denied wrongdoing, however.

All of this puts AbbVie’s investors in a challenging situation. Should they hold their shares as AbbVie just posted roughly in line fiscal results? Or, should they be concerned enough about the thousands of lawsuits to dump their ABBV stock holdings?

There are other factors to consider, as well. For example, AbbVie now has a trailing 12-month price-to-earnings (P/E) ratio of 20.38. This might make the stock attractive to value-focused investors.

Also, AbbVie pays a forward annual dividend yield of 3.73%. This could make ABBV stock more enticing to investors who like to earn regular income.

In any case, the shares were down 6% this morning, so it looks like some traders decided to sell. It’s up to you, as a prospective investor, to decide whether AbbVie’s lawsuits are a deal breaker, or no big deal.

On the date of publication, David Moadel did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

David Moadel has provided compelling content – and crossed the occasional line – on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.


Article printed from InvestorPlace Media, https://investorplace.com/2022/07/abbv-stock-slips-as-abbvie-faces-opioid-lawsuits/.

©2022 InvestorPlace Media, LLC